SQZ Biotechnologies Co
OTC:SQZB

Watchlist Manager
SQZ Biotechnologies Co Logo
SQZ Biotechnologies Co
OTC:SQZB
Watchlist
Price: 0.024 USD Market Closed
Market Cap: 707.8k USD

SQZ Biotechnologies Co
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SQZ Biotechnologies Co
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
SQZ Biotechnologies Co
OTC:SQZB
Total Receivables
$400k
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$12.8B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$5.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$8.5B
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.7B
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

SQZ Biotechnologies Co
Glance View

Market Cap
708k USD
Industry
Biotechnology

SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2020-10-30. The firm is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in human papillomavirus (HPV) plus tumors. The company is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that is designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

SQZB Intrinsic Value
Not Available

See Also

What is SQZ Biotechnologies Co's Total Receivables?
Total Receivables
400k USD

Based on the financial report for Dec 31, 2022, SQZ Biotechnologies Co's Total Receivables amounts to 400k USD.

What is SQZ Biotechnologies Co's Total Receivables growth rate?
Total Receivables CAGR 3Y
-42%

Over the last year, the Total Receivables growth was -87%. The average annual Total Receivables growth rates for SQZ Biotechnologies Co have been -42% over the past three years .

Back to Top